Key result
Rivaroxaban eutectics with acidic coformers improve solubility, dissolution, and bioavailability without compromising stability.
Formulating rivaroxaban as eutectics with acidic coformers improves its solubility and bioavailability while maintaining stability.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for eutectic rivaroxaban formulations; human trials needed before clinical consideration.
Six acidic coformers were used to prepare eutectics of rivaroxaban (RXB), a factor Xa inhibitor. The eutectics displayed improved solubility, dissolution rate, and bioavailability of RXB, without compromising on its stability.
No takes yet. Share an insight, caveat, or question.
Shaligram et al. (2023) studied this question. Rivaroxaban eutectics prepared with acidic coformers demonstrated improved solubility, dissolution rate, and bioavailability without compromising the drug's stability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: